FDA Issues Complete Response Letter for neffy® (epinephrine

Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under...

Related Keywords

United States ,Laura Oneill ,Richard Lowenthal ,Monique Allaire ,Justin Chakma ,Strategic Communications ,Exchange Commission ,Nasdaq ,Advisory Committee ,Drug Administration ,Pharmaceuticals Inc ,European Medicines Agency ,Committee For Medicinal Products Human ,Complete Response Letter ,New Drug Application ,Allergic Reactions ,Formal Dispute Resolution Request ,Medicinal Products ,Human Use ,Typei Allergic Reactions ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Contact ,Media Contact ,Nasdaq Spry ,Ars Pharmaceuticals ,Nc ,